NKTR Nektar Therapeutics

$NKTR This is how I know we got something coming Thursday 8 am EST. The following dermatologist were sent to attend to EADV conference in Vienna to present the latest data . Not anybody can attend and present with late entrances. Apparently this is the largest dermatology assmbly in Europe with 17,000 in attendees. This is huge If the data was insufficient they would not be sending these dermatologist to explain to other dermatologist how and why rezpeg works . Up until today I was nervous thinking that the data was insufficient. But I am thinking now the data is beyond expectations. David Rosmarin, MD Chair of Dermatology, Indiana University School of Medicine. He is presenting the 52-week REZOLVE-AA alopecia areata data (including off-treatment durability) as an oral session. He has been a public advocate for advancing the Treg approach in alopecia areata and has discussed the Phase 2b results at AAD as well. Emma Guttman-Yassky, MD, PhD Waldman Professor and Chair of Dermatology, Icahn School of Medicine at Mount Sinai. She is giving the late-breaking oral on multi-omic / biomarker findings from a REZOLVE-AD sub-study run at Mount Sinai. She is one of the most cited investigators in atopic dermatitis immunology and frequently leads or comments on novel-mechanism trials. Jonathan Silverberg, MD, PhD, MPH — discussed REZOLVE-AD 16-week results. Benjamin Ungar, MD, Director of the Alopecia Center of Excellence in the same Waldman department, is appearing with Nektar management around the EADV presentations.That group is a high-volume academic center for both atopic dermatitis and alopecia areata and is a natural Phase 3 site. Enough said !!! Get your helmets on cause we ride Thursday am

$NKTR One for the Bionervewrecking Hall of Fame without a doubt. Respect if you are long here for years.

$NKTR That’s a B/S excuse and obviously the only reason that they could come up with to justify them to breach their contract with NKTR. All drugs that require injections are subject to reactions, even the butt load of drugs that had already been approved for Eli Lilly by the FDA. so i guess Eli Lilly needs to drop over half of the medications if they are that concerned. Straight up liars

$NKTR this is a great opportunity for those who bought late. this will go back up to $140 and up. hold your position buy but don’t sell. this is Gold. too good of a product.

$NKTR we need to have the SEC and the the DOJ to investigate who’s all conspiring against NKTR. This is clearly blatant, this is truly a team effort of haters.

$NKTR Investor and Analyst Call and Webcast on Thursday, October 1, 2026 at 8:00 AM ET. NKTR will be conducitng 3 presentations at EADV . Check NKTR website for more information. Also a Presentation Date and Time: Thursday, October 1st 16:30 – 16:40 CET. (This is 1230 EST). This is in Vienna on same day as conference call. Location: Hall N

$NKTR The recent verdict against LLY is a significant vindication for NKTR. It clearly demonstrates that LLY's previous claim—that Rezpeg was worthless—has been proven wrong, as LLY's lawyers now acknowledge Rezpeg's value. NKTR is officially moving on from the past.

$NKTR Market cap has dropped 500M since start of the trial. I find it really hard to believe market was already pricing in a $500M win.

$NKTR now trading at 1x cash. Thank you to the silly simple minded day traders that have zero long-term vision. Load the boat. 🚤 

$NKTR This is brutal. At this rate, we’ll be testing support in the mid-30s within a few days.

$NKTR The average analyst price target is 141.40. They also released good news today. This is a screaming buy imo.

$NKTR Riley, Wainwright, and Blair affirm their buy ratings. Citi says the selloff presents an attractive buying opportunity. Yet the purge continues. When, if ever, might we see green?

$NKTR This data is hard to sift thru but the most important finding is many patients continued to grow hair while off drug. My initial thoughts before today were the numbers prior to todays release were low. But many people do not respond. Nonetheless rezpeg patients will be induced one every two or 26 times in a year. Compared to a once daily JAKi pill compared. Compared to Abbvie Zumiliokbart IL 13 antibody they will get twice per year then twice the second year. I am glad that rezpeg is still in the game.

$NKTR So today’s call brought good news and they take stock down hard ?? What am I missing .

$NKTR The Paid per post short hoes are in full force here . Trash ! Daddy Short have their BOTS out in full force . Paid by LLY … trying to destroy their competition , sadly did not pay enough for their crooked ways .. block away !

$NKTR Some ahole short spreading BS rumors , they should report that crook and put him in Jail , rumors is what they feed on and make people lose their mind . Company still has 1 billion in the Bank !! Whatever the results from Trial , they have dropped this $14 plus and a lot more than that from last raise at $92 a share . I am hoping for a good verdict as that will trigger a jump back toward $90 . This can move f up fast , 3.3 mill shares traded today . Mostly in the afternoon after rumors hit . No news , just scare tactics !

$NKTR Block out the noise and stay the course. I’m still adding at these ridiculously low prices.

$NKTR Finally a Green Day today. Down side should be limited at this price especially with all that cash on hand.

$NKTR Korn should consider spending the $90 lly award buying back 2mm shares of stock at this price

$NKTR Nothing has changed with the company, except that someone shorting it is causing stop losses to trigger. Patiently waiting to see where they take it, maybe even down to close the gap which likely means all the technical traders jumped in. That’s probably where I will double my position or just a little higher, 40-42. I got the cash and I got the time.